Idelalisib

Grey

Brand Name(s):Zydelig

Indication:Leukaemia-chronic lymphocytic (CLL)

Rationale:2

Considered:Oct-14

Review Date:Aug-22

Comments:
Drug Safety Update: Measures to minimise risk of infection in all patients
Sept 2016
…………………………
Drug Safety Update New interim treatment recommendations
May 2016
…………………………
NICE TA 359
Idelalisib for treating chronic lymphocytic leukaemia
Full document can be found at:http://www.nice.org.uk/guidance/ta359/resources/idelalisib-for-treating-chronic-lymphocytic-leukaemia-82602676706245
October 2015